Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...

On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West ...

Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...

Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) results for EYLEA HD (aflibercept) Injection 8 mg in ...

D Molecular Therapeutics (FDMT) announced positive initial interim 52-week data from the Phase 2b Population Extension cohort of the ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

Addressing a preliminary injunction in patent litigation related to the Biologics Price Competition and Innovation Act (BPCIA), the US Court ...

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) tumbled 21% following the release of positive clinical trial results for their DURAVYU™ treatment, confounding analysts who viewed the ...